SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: The Gambler who wrote (1025)1/17/1998 9:14:00 PM
From: D.Right  Respond to of 2173
 
Dear Gambler (we are all gamblers in a sense):

Thanks for the information. I do check there from time to time, but I missed this one somehow. It is good to know that both the Chairman and the CEO bought it on the way down. I am sure they didn't really need the last 15,000 shares to get rich, however it is still a good way to show investors they are very confident of their drug.

D.Right



To: The Gambler who wrote (1025)1/18/1998 11:08:00 AM
From: tonyt  Read Replies (1) | Respond to of 2173
 
Interesting. Insiders avg pur price by the Chairman and a Director in Dec was $5.

Has anyone heard a report on Amylin's presentation last week?
(FWIW, the only biotech that I follow that did well last week was VICL, and they didn't even present at H&Q -- All it needed was a mention in BusinessWeek by CTSL. BTW, CTSL is still recomending AMLN)

--Tony


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News